Cubist Pharmaceuticals to Announce Fourth Quarter 2004 Earnings on Jan

    Business Editors/Medical Editors
    BIOWIRE2K

    LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 3, 2005--Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that it will release financial results for the fourth quarter and full year ended December 31, 2004 on Tuesday, January 25, 2005 prior to the opening of the U.S. financial markets. The company will host a live conference call and webcast to discuss the results at 10:30 AM Eastern Time that same day.
    Domestic participants can access the call by dialing the Toll-Free number 1-800-473-6123. International participants should dial 973-582-2706. A replay will be available approximately 3 hours after the conclusion of the call and can be accessed by dialing Toll-Free 877-519-4471 and using Conference ID: 5506269. This call will be webcast by Vcall and can be accessed at www.cubist.com. Please log on to the webcast 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
    Also announced is Cubist's participation at the 23rd Annual JP Morgan Healthcare Conference. Michael W. Bonney, President and Chief Executive Officer of Cubist is scheduled to present on Thursday, January 13th at 1:30 PM Pacific Time at the Westin St. Francis Hotel in San Francisco. To access the live audio broadcast and slide presentation, please log on to http://equityconferences.jpmorgan.com and select JP Morgan Healthcare Conference webcast link. Further webcast information can be found at www.cubist.com.

    About Cubist

    Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of antiinfective products that meet unmet medical needs. In the U.S., Cubist markets Cubicin(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. CUBICIN is currently the only once-daily bactericidal antibiotic approved in the U.S. with activity against both methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MSSA and MRSA) in complicated skin and skin structure infections. Cubist's pipeline includes HepeX-B(TM), a monoclonal antibody biologic currently in the second of two Phase 2 trials to determine its potential for the prevention of infection by the Hepatitis B virus (HBV) in liver transplant patients, and research efforts focused on novel members of the lipopeptide class of molecules and on natural products discovery. Cubist is headquartered in Lexington, MA.

    Cubist Safe Harbor Statement

    Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and such statements are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cubist. These factors include, but are not limited to: (i) the level of acceptance of CUBICIN by physicians, patients, third-party payors, and the medical community generally; (ii) Cubist's ability to continue to develop, secure additional regulatory approvals for, and successfully market, CUBICIN; (iii) Cubist's ability to manufacture CUBICIN on a commercial scale; (iv) commercialization of products that are competitive with CUBICIN; (v) Cubist's ability to discover or in-license drug candidates; (vi) Cubist's ability to successfully develop drug candidates in its pipeline, including HepeX-B; (vii) Cubist's ability to successfully commercialize any product or technology developed by Cubist; (viii) Cubist's ability to establish and maintain successful manufacturing, sales and marketing, distribution, and development collaborations; (ix) legislative or regulatory changes adversely affecting Cubist or the biopharmaceutical industry; (x) Cubist's ability to protect its intellectual property and proprietary technologies; and (xi) Cubist's ability to finance its operations. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cubist's recent filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in such filings.

    Cubist and Cubicin are registered trademarks of Cubist Pharmaceuticals, Inc.; HepeX-B is a trademark of XTL Biopharmaceuticals Ltd.

    Additional information can be found at Cubist's web site at www.cubist.com

--30--GK/bo*

CONTACT: Cubist Pharmaceuticals, Inc. Michelle Faulkner, 781-860-8414 michelle.faulkner@cubist.com

KEYWORD: MASSACHUSETTS INDUSTRY KEYWORD: BANKING PHARMACEUTICAL BIOTECHNOLOGY EARNINGS CONFERENCE CALLS SOURCE: Cubist Pharmaceuticals, Inc.

Copyright Business Wire 2005